Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Fungal colonization profiles from four different anatomical sites were evaluated in 266 neutropenic cancer patients receiving intensive cytotoxic therapy for acute leukaemia or for autologous marrow transplantation. At the beginning of chemotherapy patients were allocated randomly to receive oral fluconazole 400 mg daily or an identical placebo until prophylaxis failure or marrow recovery. Candida albicans colonization was reduced from 30 to 10% in the fluconazole recipients while it increased from 32 to 57% in the placebo patients (P<0.001). By the end of prophylaxis, colonization with non-albicans Candida species increased from 7 to 21% and 8 to 18% in the fluconazole and placebo patients, respectively (P = 0.396). Although Candida glabrata was isolated more frequently at the end of the prophylactic period in the fluconazole patients than in the placebo patients (16 versus 7%), only one definite invasive C. glabrata infection was noted. Overall, definite invasive fungal infections were documented in 26 patients [four fluconazole versus 22 placebo patients (P< or =0.001)]. In 23 (92%) patients the infections were caused by persistently colonizing or newly acquired organisms. While probable invasive fungal infections were noted in five fluconazole patients, 10 placebo patients were also affected (P = 0.19). An end-of-prophylaxis colonization index >0.25 was 76% sensitive but only 69% specific for invasive fungal infection. However, a colonization index < or =0.25 at baseline had a negative predictive value of 88% for development of invasive fungal infection. Fluconazole prophylaxis decreased colonization by fungi and subsequent invasive fungal infections in neutropenic cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937
Candida Colonization and Subsequent Infections in Critically III Surgical Patients
Pittet, D., Monod, M., Suter, P. M., Frenk, E., & Auckenthaler, R. (1994) · Annals of Surgery · doi:10.1097/00000658-199412000-00008 · Cited by 798
Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality.
Fraser, V. J., Jones, M., Dunkel, J., Storfer, S., Medoff, G., & Dunagan, W. C. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.3.414 · Cited by 679
Cited by
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Requirement of Interleukin‐17A for Systemic Anti– Candida albicans Host Defense in Mice
Huang, W., Na, L., Fidel, P. L., & Schwarzenberger, P. (2004) · The Journal of Infectious Diseases · doi:10.1086/422329 · Cited by 859
Interventions for treating oral mucositis for patients with cancer receiving treatment
Clarkson, J. E., Worthington, H. V., Furness, S., McCabe, M., Khalid, T., & Meyer, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001973.pub4 · Cited by 674
Invasive Fungal Pathogens: Current Epidemiological Trends
Pfaller, M. A., Pappas, P. G., & Wingard, J. R. (2006) · Clinical Infectious Diseases · doi:10.1086/504490 · Cited by 448
A Multicenter, Randomized Trial of Prophylactic Fluconazole in Preterm Neonates
Manzoni, P., Stolfi, I., Pugni, L., Decembrino, L., Magnani, C., Vetrano, G., Tridapalli, E., Corona, G., Giovannozzi, C., Farina, D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065733 · Cited by 356
Robenshtok, E., Gafter-Gvili, A., Goldberg, E., Weinberger, M., Yeshurun, M., Leibovici, L., & Paul, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3851 · Cited by 298
A systematic review of oral fungal infections in patients receiving cancer therapy
Fungal Infections Section, O. C. S. G., Lalla, R. V., Latortue, M. C., Hong, C. H., Ariyawardana, A., D’Amato-Palumbo, S., Fischer, D. J., Martof, A., Nicolatou-Galitis, O., Patton, L. L., et al. (2010) · Supportive Care in Cancer · doi:10.1007/s00520-010-0892-z · Cited by 265
Bow, E. J., Laverdière, M., Lussier, N., Rotstein, C., Cheang, M. S., & Ioannou, S. (2002) · Cancer · doi:10.1002/cncr.10610 · Cited by 258
Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?
Charlier, C., Hart, E., Lefort, A., Ribaud, P., Dromer, F., Denning, D. W., & Lortholary, O. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki473 · Cited by 184
Risk factors for albicans and non-albicans candidemia in the intensive care unit*
Chow, J. K., Golan, Y., Ruthazer, R., Karchmer, A. W., Carmeli, Y., Lichtenberg, D. A., Chawla, V., Young, J. A., & Hadley, S. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e31816fc4cd · Cited by 154
Mutants with heteroresistance to amphotericin B and fluconazole in Candida
Claudino, A. L. R., Peixoto Junior, R. F., Melhem, M. S. C., Szeszs, M. W., Lyon, J. P., Chavasco, J. K., & Franco, M. C. (2009) · Brazilian Journal of Microbiology · doi:10.1590/s1517-83822009000400028 · Cited by 12
Metadata
- Authors
- Laverdiere, M.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-12-01
- Volume
- 46
- Issue
- 6
- Pages
- 1001-1008
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2099975106
- Cited by
- 83
- References
- 3
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.